Craft

Crinetics Pharmaceuticals

Stock Price

$56.3

2024-10-29

Market Capitalization

$5.1 B

2024-10-29

Revenue

$7.7 M

FY, 2025

Crinetics Pharmaceuticals Summary

Company Summary

Overview
Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company that develops and commercializes therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist for the treatment of acromegaly; CRN04894, an oral adrenocorticotrophic hormone antagonist for the treatment of Cushing's and congenital adrenal hyperplasia diseases, etc.
Type
Public
Status
Active
Founded
2008
HQ
San Diego, CA, US | view all locations
Website
https://crinetics.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • R. Scott Struthers

    R. Scott Struthers, Founder, Chief Executive Officer, Director

  • Marc Wilson

    Marc Wilson, Chief Financial Officer

  • Alan S. Krasner

    Alan S. Krasner, Chief Medical Officer

  • Jeff Knight

    Jeff Knight, Chief Operating Officer

    LocationsView all

    1 location detected

    • San Diego, CA HQ

      United States

      6055 Lusk Blvd

    Crinetics Pharmaceuticals Financials

    Summary Financials

    Revenue (Q1, 2026)
    $10.7M
    Gross profit (Q1, 2026)
    $10.5M
    Net income (Q1, 2026)
    ($127.8M)
    Cash (Q1, 2026)
    $114.3M
    EBIT (Q1, 2026)
    ($140.4M)
    Enterprise value
    $5.0B

    Footer menu